Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Ankylosing Spondylitis: Treat to Target

From the College  |  October 18, 2022

This session at ACR Convergence 2022, on Monday, Nov. 14, 2022, from 9–10 a.m. EST, will examine guidelines and current evidence regarding the management and outcomes of patients with ankylosing spondylitis (AS). Alexis Ogdie, MD, a rheumatologist and associate professor of Medicine at the University of Pennsylvania, Philadelphia, will present data to highlight the evolution of treatment strategies. The presentation will focus on evidence for state-of-the-art treatments in AS, including assessing whether treat to target is a paradigm that fits AS. The current state of evidence and what further studies will be useful to support or refute the use of treat to target in AS will be discussed.

Watch this space for our full report on this important session.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Share: 

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – AS

Related Articles
    Biophoto Associates / Science Source

    A Stiff Man: A Case Study in Ankylosing Spondylitis

    July 12, 2017

    First Appearances I watched the old man, his back painfully bent, shuffle toward the scale. A blocky rigidity draped over him. His feet seemed stuck to the floor. His head hung heavily over his chest. Observing him from the end of the hallway, instead of a face, I saw only a mound of shaggy, matted…

    Chu KyungMin / shutterstock.com

    The Bath Ankylosing Spondylitis Functional Index’s History & Patient View

    September 26, 2019

    Sir William Osler, widely regarded as one of the greatest physicians of the 20th century, once said, “He who studies medicine without books sails an uncharted sea, but he who studies medicine without patients does not go to sea at all.”1 This sentiment is particularly true in the field of rheumatology, in which understanding the…

    The Why & What of the ACR's Clinical Practice Guidelines

    The Why & What of the ACR’s Clinical Practice Guidelines

    February 18, 2018

    With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences